Applying the thresholds for clinical importance for fourteen key domains of the EORTC QLQ-C30: A Latent Class Analysis of Cancer Survivors.

Keaver, L., & McLaughlin, C. (2021). Applying the thresholds for clinical importance for fourteen key domains of the EORTC QLQ-C30: A Latent Class Analysis of Cancer Survivors. Supportive Care in Cancer, 29, 7815-7823. Advance online publication. https://doi.org/10.1007/s00520-021-06292-9

Link to publication record in Ulster University Research Portal

Published in:
Supportive Care in Cancer

Publication Status:
Published online: 25/06/2021

DOI:
10.1007/s00520-021-06292-9

Document Version
Author Accepted version

General rights
Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact pure-support@ulster.ac.uk.
Applying the thresholds for clinical importance for fourteen key domains of the EORTC QLQ-C30: A Latent Class Analysis of Cancer Survivors.

Abstract
A person’s quality of life is impacted from the beginning of their oncology experience. One of the most common tools to measure quality of life is the EORTC QLQ-C30. The absolute scores it produces can be difficult to interpret in the clinical setting and thresholds to help identify those who require intervention have recently been introduced. The aim of this research was to identify heterogeneity of these thresholds for clinical importance using latent class analysis in cancer survivors (those undergoing and those who have completed treatment) attending a hospital in the north west of Ireland. We identified 3 distinct classes of cancer survivors, using Mplus 6.11: high clinical impact (13.9%), compromised physical function (40.3%) and low clinical impact (45.9%). The compromised physical function group were slightly more likely to be older (OR=1.042, p<.05, CI=1.000–1.086), not employed (OR=8.347, p<.01, CI=2.092–33.305), have lower PG-SGA scores (OR=.826, p<.001, CI=.755–.904), and not have been diagnosed in the last two years (OR=.325, p<.05, CI=.114–.923) compared to the high clinical impact group. The low clinical impact group were more likely to be female (OR=3.288, p<.05, CI=1.281–1.073), not employed (OR=10.129, p<.01, CI=2.572–39.882), have a lower BMI (OR=.921, p<.05, CI=.853–.994) and lower PG-SGA scores (OR=.656, p<.001, CI=.573–.750) than the high clinical impact group. Functional and symptom issues impact on quality of life and therefore identifying those of clinical importance is crucial for developing supportive care strategies.

Keywords: Clinical Importance, Quality of Life, Symptom Burden, Functioning, Thresholds
Introduction

A person’s quality of life is impacted from the beginning of their oncology experience [1] and those with cancer often report strong impairments in Quality of Life (QoL) compared to healthy populations [2, 3]. Side effects of treatment such as anxiety, depressed mood, pain, fatigue, dyspnea and appetite loss can impair activities of daily living in those with cancer, impacting on QoL [4, 5]. Cancer-related fatigue, experienced as emotional, physical or cognitive exhaustion, is one of the most commonly reported side effects of cancer and treatment [6-8] and can significantly impair multiple domains of QoL including physical functioning, cognitive functioning and emotional functioning [9, 6, 8]. Correlations with survival rates have been reported for several QoL domains [10-12] and therefore it has received much focus as a variable of importance.

One of the best ways to determine impacts of cancer on QoL is to ask patients themselves and there are a number of tools available to measure QoL in this way. One of the more commonly used is the European Organization for Research and Treatment of Cancer quality of Life Questionnaire (EORTC QLQ-C30) [13, 14]. This questionnaire assesses not just global health status but also five different functioning domains, eight symptom domains as well as financial impact. While it was often used as an outcome measure for trials it is more increasingly being used in clinical practice [15], where it appears to improve clinician-patient communication [16]. The absolute scores it produces however, can be difficult to interpret in this setting and do not indicate clearly indicate which functioning or symptom subscales require attention [17].

To better interpret the scores that this questionnaire generates, researchers have investigated cut-offs and thresholds for each of these scales to try to aid clinicians in easily identifying clinically important impairment of function or symptom burden. These have varied significantly over the years and all come with their own inherent limitations, such as using the same threshold for each of the domains [18] or use of percentiles with a general population reference point [19]. Giesinger et al., have recently developed thresholds for clinical importance based on mixed-methods work with patients and healthcare professionals to determine what makes a symptom or burden clinically important [20].

In clinical practice these thresholds will help the clinician to be able to identify symptom and functional health problems that require attention. The aim of this research was to apply these thresholds to a cohort of Irish Cancer Survivors (both undergoing and completed treatment) and to examine heterogeneity of these thresholds for clinical importance using latent class
analysis. A secondary aim was to determine whether these groups differed by select demographic and health characteristics.

**Method Section**

**Sample**

Participants were recruited through the oncology day ward and outpatient department in Sligo University Hospital between September 2019 and March 2020. Ethical approval was granted by the Research Ethics Committee at Sligo University Hospital.

**Measures**

Individuals completed a demographic questionnaire (age, gender, cancer duration, education, employment, treatment status), the EORTC QLQ-C30 [13], the Patient Generated Subjective Global Assessment Short Form (PG-SGA SF) [21] questionnaire and a handgrip strength test using a handgrip dynamometer (dominant hand, result measured in kg). Weight and height was measured by an oncology nurse and Body Mass Index (BMI) was calculated using the formula weight/height².

The PG-SGA SF is a screening tool for malnutrition risk which is considered the reference method to assess malnutrition in an oncology setting [22], it is not however, an oncology specific tool. It consists of four sections to be completed by the patient which address weight history (patient is asked to indicate current weight and height, weight one month ago, weight six months ago and also to answer the following: during the past two weeks my weight has increased, decreased, stayed the same), food intake (compared to my normal intake, I would rate my food intake during the past month as unchanged, more than usual, less than usual; individuals are then asked what type of food e.g. normal food, liquids, nutritional supplements), nutrition impact symptoms (e.g. I have had the following problems that have kept me from eating in the last two weeks, tick all the apply – list of 14 impact symptoms and option to choose and specific ‘other’) and activities/function (rate activity over the last month from
normal to severe limitations/bed bound). These were scored using standardised guidelines with a minimum of 0 and a maximum of 36 points being achievable [21]. A higher score reflects a greater risk of malnutrition.

The EORTC QLQ-C30 is a validated measure for determining Quality of Life in cancer patients. This provides scoring (0-100) for five functioning scales (physical, role, emotional, cognitive and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation and diarrhoea) and perceived financial impact. Example questions include, in the past week have you have difficulty remembering things; did you feel depressed; have you had trouble sleeping; were you limited in doing either your work or other daily activities? For the current study, the five items of the functioning subscales had favourable factor loads [23] and yielded a favourable level [24] of internal consistency (α = .77). Likewise, for the symptom and financial subscales all nine items had favourable factor loads [23] and yielded a favourable level [24] (Kline, 2000) of internal consistency (α = .70).

The thresholds for clinical importance (TCI’s) for each of the quality of life subscales was determined using the validated measures developed by Giesinger et al., [20]. Individuals were then binary categorised as meeting or not meeting this threshold. The TCI’s for the five functioning scales were: Physical Functioning (83); Role Functioning (58); Social Functioning (58); Emotional Functioning (71) and Cognitive Functioning (75). While the TCI’s for the symptom scales were: Fatigue (39); Pain (25); Nausea/vomiting (8); Sleep Disturbance (50); Dyspnoea (17); Appetite Loss (50); Constipation (50); Diarrhoea (17) and Financial Impact (17).

Materials

Proposed analytical approach

For the analysis we undertook a two-stage approach to the research. We employed Latent Class Analysis (LCA) as the main statistical approach to investigate the number of possible latent typologies within the TCI data. Using the binary observed TCI indicators, it was expected that it would identify possible typologies [25, 26] as LCA is seen as a ‘person-centred’ statistical process [26]. For each of the latent classes identified we defined a conditional model using
each of the ten binary indicators; and furthermore, all models were estimated using Mplus 6.11 [27] along with robust maximum likelihood [28]. Also, in order to avoid solutions based on local maxima, 100 random sets of start value were used alongside 20 final stage optimisations. Model fit was assessed using several information theory-based fit statistics; Akaike Information Criterion (AIC) [29], Bayesian Information Criterion (BIC) [30] and the sample-sized-adjusted BIC (ssaBIC) [31]. The model that produces the lowest values on each of these is the best fitting model. Additionally, the Lo-Mendell-Rubin adjusted Likelihood Ratio Test (LRT) [32] has also been employed to assist in class enumeration, where a non-significant value suggests a class lower should be considered. Nylund et al. [33] have identified the benefits of the LRT [32] over the BIC in aiding decision making over the number of classes to accept.

**Multinominal Logistic Regression**

Two multinominal logistic regressions were carried out to explore the relationship between (i) key demographic variables (age, education (Primary/Non-Completed Secondary; Completed Secondary/Training; Third Level (BA, BSc, Diploma); Graduate Degree/Higher), gender, and employment (this binary variable allowed participants to be classified as (1 = No) not working (retired/unemployed) and (Yes = 0) working (full-time, part-time, or self-employed) at present) and (ii) health related factors (BMI (kg/m²), Handgrip (kg), PG-SGA score, diagnosis duration (≤2 years or >2 years) and treatment status (currently receiving treatment or completed treatment )) with participant classifications.

**Results Section**

**Characteristics**

232 participants were recruited. The cohort had a mean age of 63.5 (±11.9) years. The majority were female (n=138, 61.1%), diagnosed less than five years (n=167, 73.9%) and almost half (n=112, 48.5%) were retired. The majority were currently receiving treatment (n=159, 70.4%). The main treatment type being received was chemotherapy (n=129, 81.1% of those receiving treatment), followed by hormonal therapy (n=19, 11.9% of those receiving treatment). The
most common diagnosis was breast cancer \( (n=58, 25.7\%) \), followed by colorectal \( (n=32, 13.8\%) \), haematological \( (n=28, 21.1\%) \), lung \( (n=12, 5.2\%) \) and upper gastrointestinal/liver \( (n=10, 4.3\%) \). Gynaecological, urinary, head and neck, skin and bone cancers made up the remaining cases.

**Descriptive trends of indicators**

Table 1 presents the descriptive breakdown for each of the TCI indicators to be included within the LCA model. A total of fourteen indicators were employed and each was measured on a No (0) or Yes (1) binary response set. Descriptive analysis reported that the most experienced QOL-CI issue was dyspnoea \( (40.9\%) \) while the least experienced were appetite loss \( (12.6\%) \) and constipation \( (12.6\%) \).

**Fit indices and latent class analyses**

To explore the number of TCI typologies, analysis started firstly with a one class model and continued until models failed to add significantly to the previous model. In other terms once the conditional model failed to add statistically to its predecessor, the analysis would cease. Each of the TCI model fit indices are displayed in Table 2. A three-class model was selected as the AIC was lower in the three-class solution \( (AIC = 3392.618) \) than the two-class solution \( (AIC = 3443.829) \). The BIC was reported to be more favourable for the three-class model \( (BIC = 3544.084) \) than the four-class model \( (BIC = 3575.481) \). Additionally, since the four-class model added nothing significantly \( (\text{LRT} = 50.240, p = .191) \) to the three-class model, the three-class model was preferred. Lastly, a three-class provides a more parsimonious explanation than a four-class.

Table 3 contains the posterior probabilities for each of the three-classes along with associated descriptive information. Regarding class size, it is clear from the table that the largest group is the second class \( (n = 106, 45.9\%) \) and this group is characterised by very low probability of experiencing any of the TCI indicators. Posterior probabilities ranged from 0.01 to 0.23. Thus, this class of participants were labelled “low clinical impact” based on their probability of low clinical importance. The next largest in participant size was the third group \( (n = 93, 40.3\%) \) and interestingly this class was characterised by three TCI indictors of higher clinical
importance. More specifically, higher posterior probabilities were reported for physical functioning (0.65), fatigue (0.52) and dyspnoea (0.52); thus, identifying this group as “compromised physical function”. Lastly, the smallest class (n = 32, 13.9%) was characterised by reporting higher posterior probability scores than the other two groups. All indictors had a posterior probability score higher than 0.50 except for two indicators; namely appetite loss (.46) and constipation (.29). Examining the reported probabilities this group was labelled “high clinical impact”. A graph was also developed to aid the interpretation of the probabilities and how the three classes distinguish from each other across each of the symptom indicators (Figure 1).

**Multinominal Logistic Regression**

In model 1, age had only a significant effect within Class 3 (impaired physical functioning) (OR = 1.042, p < .05, CI = 1.000 – 1.086) but not Class 2 (low clinical impact) in comparison to the reference group (high clinical impact). Individuals in this group were slightly more likely to be older than the reference Class. There was no significant effect by age for education across any of the classes. Gender was only reported significant in Class 2 (low clinical impact) (OR = 3.288, p < .05, CI = 1.281 – 1.073). Here individuals were over 3 times more likely to be female in this group in comparison to Class 1 (high clinical impact). Employment status was reported to have a significant effect on both Classes (Class 2: OR = 10.129, p < .01, CI = 2.572 – 39.882; Class 3: OR = 8.347, p < .01, CI = 2.092 – 33.305) in comparison to the reference Class; more specifically, non-workers were over 10 times more likely to be in Class 2 (low clinical impact) than the referent class (high clinical impact), while Class 3 individuals (impaired physical functioning) were over 8 times more likely to be not-working in comparison to the referent Class (Table 4).

Compared to Class 1 (high clinical impact) within Model 2, the odds of belonging to Class 2 (low clinical impact) decreased significantly by having higher BMI (OR = .921, p < .05, CI = .853 - .994) and PG-SGA (OR = .656, p < .001, CI = .573 - .750) scores. Similarly, the odds of belonging to Class 3 (impaired physical functioning) decreased significantly for those with higher PG-SGA (OR = .826, p < .001, CI = .755 - .904), but also for those diagnosed within the past two years (OR = .325, p < .05, CI = .114 - .923). All other associations were reported non-significant (Table 5).
Discussion

We identified 3 distinct classes of cancer survivors based on the thresholds for clinical importance for each of the 14 subscales of the EORTC QLQ-C30. Approximately 46% of the cohort were classified as having a very low probability of meeting the threshold for clinical importance for any of the QoL scales. The remaining participants were classified into one of two classes which demonstrated clinical importance for either the majority of QOL scales or those related to physical functioning e.g. physical function, fatigue and dyspnoea.

The distinct classes of low clinical impact, compromised physical function and high clinical impact indicates that classifying quality of life by an average score may be limiting. In that case the clinical implications of the various domains may not be evident. Almost 41% of the total cohort met the threshold for clinical importance for dyspnoea, 43% for physical functioning and 36% for fatigue, none of which will be evident by looking at the overall Global Health Status score.

Those in the compromised physical function group represented 40% of the total cohort and are likely to experience clinically important impairments in physical function, fatigue and dyspnoea. Fatigue is one of the most common and impactful symptoms experienced by those with cancer and is associated with profound psychological distress [34, 6]. It has been rated as one of the more troublesome symptoms and impacts more negatively on activities of daily living than any other cancer related symptom [9, 35]. Physical function has been related to fatigue [36], is a frequent consequence of cancer and its treatments, and impacts on quality of life and contributes to disease burden and psychosocial distress [37]. Dyspnoea can impact on activities of daily living and in particular physical activities [4]. Increased physical activity has been associated with reduced cancer associated mortality [38] as well as a reduced symptom burden [39, 40]. Exercise interventions have been shown to have beneficial effects on QoL, physical function, social function, and fatigue [41]. All three symptoms in this class will impact on an individual’s ability to undertake physical activity or partake in exercise-based rehabilitation and therefore prevent them from experiencing these benefits.

Fourteen percent of the cohort belonged to the high clinical impact group. Though the smallest group, they were the most important as they identified with higher clinical importance in most
of the QoL indicators, except for appetite loss and constipation. They were more likely to have higher PG-SGA scores, meaning a higher risk of malnutrition than those in the compromised physical function group and the low clinical impact group. Nutritional status has been shown to be a significant predictor of QoL in those with cancer and therefore this finding is not surprising [42]. Cancer and its treatment can lead to changes in physiological and psychological domains, which in turn can negatively influence a patient's QoL through its impacts on nutritional status [43]. Nutrition support should therefore be included as part of all oncology care. The treatment of symptoms and impaired function will help improve overall quality of life.

Those in the high clinical impact group were more likely to be diagnosed in the last two years than those in the compromised physical function group. This indicates that while symptom burden may be higher in this cohort in the initial years after diagnosis the symptoms associated with physical function impairment such as fatigue can persist much longer. Previous work has indicated that up to 30% of cancer survivors can experience this symptom for several years after diagnosis [44]. Those in the higher symptom burden group were also more likely to be younger than those in the impaired physical function group. This is a topic of debate where some studies have shown similar findings where those who were younger experienced a higher symptom burden [45], while other studies have not agreed with this [46, 47]. Some potential reasons for younger individuals being more likely to be in the high clinical impact group could be that there is a higher likelihood of them receiving aggressive therapies [48], a higher level of functioning and therefore greater expectations for the resumption of pre-cancer abilities [49] or in some cases a higher prevalence of advanced cancers [50].

Interestingly, those in the low clinical impact group were more likely to be female than those in the high clinical impact group. Gender based differences in symptom burdens experienced by those with cancer tends to be inconsistent across the literature [51, 52, 45]. The only socioeconomic based difference that was observed in class membership was that those in the compromised physical function and low clinical impact group were more likely to not be working, however a large proportion of our cohort was retired which may account for this finding. Those in the low clinical impact group were more likely to be older which would support this. In addition, those in the compromised function group were more likely to be
female and this is a group that can be more likely to be homemakers or work part-time which could also explain this finding.

Importantly, this research through the identification of these distinct classes will allow clinicians to better identify those at need for intervention. This is the first study to implement the thresholds for clinical importance using LCA and therefore there are no previous studies to compare to, however previous work which implemented LCA for the health related QoL scores reported four distinct classes in lung cancer survivors, three of which are similar to those reported in this study: high health related quality of life (HRQOL), low HRQOL and mobility/usual activities impairment [53]. This study also reported 46% of the cohort in the high HRQOL class, identical to the 46% we report as being in the low clinical impact group.

There are limitations to our study. First, the current findings are specific to our cohort and analysis should be repeated to validate our findings. Second, for those who have completed treatment the EORTC QLQ-C30 may not adequately reflect the physical and psychosocial problems experienced during this stage. Issues such as fear of recurrence or returning to work may become more common, however the EORTC QLQ-C30 focusses more on acute and treatment-related symptoms. Finally, the data was collected into the early months of 2020 and therefore some domains could have been impacted by the early stages of the Covid-19 pandemic.

Conclusion

This research identified three distinct classes of cancer survivors based on the thresholds of clinical importance for fourteen key domains of the EORTC QLQ-C30 questionnaire that will help clinicians to better identify those at need for intervention. Functional and symptom issues impact on quality of life and therefore identifying those of clinical importance is crucial for developing supportive care strategies.

Acknowledgements

We would like to thank all those who took the time to take part in this study.
### Table 1: QOL-CI indicators experienced by the cohort

| Indicators of Clinical Importance | No  | %   | Yes* | %   |
|----------------------------------|-----|-----|------|-----|
| Physical Functioning             | 131 | 57% | 99   | 43% |
| Role Functioning                 | 176 | 76.2% | 55  | 23.8% |
| Emotional Functioning            | 162 | 71.4% | 65  | 28.6% |
| Cognitive Functioning            | 157 | 68% | 74   | 32% |
| Social Functioning               | 170 | 73.9% | 60  | 26.1% |
| Fatigue                          | 148 | 64.3% | 82  | 35.7% |
| Nausea                           | 171 | 74% | 60   | 26% |
| Pain                             | 166 | 71.9% | 65  | 28.1% |
| Dyspnoea                         | 136 | 59.1% | 94  | 40.9% |
| Sleep Disturbances               | 156 | 67.8% | 74  | 32.2% |
| Appetite Loss                    | 202 | 87.4% | 29  | 12.6% |
| Constipation                     | 202 | 87.4% | 29  | 12.6% |
| Diarrhoea                        | 178 | 77.1% | 53  | 22.9% |
| Financial                        | 145 | 63.3% | 84  | 36.7% |

*indicates individuals meet the threshold for clinical importance for this quality of life measure

### Table 2: Latent class fit indices for two to four class solutions

| Classes | LL  | Par | AIC   | BIC   | LRT   | p   |
|---------|-----|-----|-------|-------|-------|-----|
| 1       | -1865.728 | 14 | 3759.456 | 3807.649 | --   | --  |
| 2       | -1692.914 | 29 | 3443.829 | 3543.659 | 345.627 | .000 |
| 3       | **-1652.309** | 44 | **3392.618** | **3544.084** | **81.211** | .039 |
| 4       | -1627.189 | 59 | 3372.378 | 3575.481 | 50.240 | .191 |

*Note. AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; LRT = Lo-Mendell-Rubin likelihood ratio test. Best fitting LCA model in bold.*
Table 3: Descriptive information regarding that three classes that arose from LCA*

| Indicators       | High Clinical Impact | Low Clinical Impact | Compromised Physical Function |
|------------------|----------------------|---------------------|-------------------------------|
| Physical Functioning | 0.85                 | 0.08                | 0.65                          |
| Role Functioning  | 0.65                 | 0.04                | 0.30                          |
| Emotional Functioning | 0.78               | 0.07                | 0.34                          |
| Cognitive Functioning | 0.69                | 0.12                | 0.40                          |
| Social Functioning | 0.82                 | 0.05                | 0.29                          |
| Fatigue          | 0.93                 | 0.00                | 0.52                          |
| Nausea           | 0.82                 | 0.11                | 0.22                          |
| Pain             | 0.87                 | 0.08                | 0.29                          |
| Dyspnoea         | 0.63                 | 0.22                | 0.52                          |
| Sleep Disturbances | 0.80                 | 0.20                | 0.28                          |
| Appetite Loss    | 0.46                 | 0.01                | 0.13                          |
| Constipation     | 0.29                 | 0.04                | 0.15                          |
| Diarrhoea        | 0.57                 | 0.19                | 0.15                          |
| Financial        | 0.64                 | 0.32                | 0.33                          |

| Percentage       | 13.9                  | 45.9                | 40.3                          |
| n                | 32                    | 106                 | 93                            |

Note: Higher probabilities (>0.50) for meeting the threshold of clinical importance for each of the QoL domains are bolded.

*231 were successfully classified by LCA.
Table 4: Odds ratios, confidence intervals (95%) for demographic factors

| Reference Group: Class 1 | B    | SE   | OR   | 95% Confidence Interval |
|--------------------------|------|------|------|-------------------------|
| **Class 2**              |      |      |      |                         |
| Age                      | .030 | .021 | 1.030| .989/ 1.073             |
| Education                | .353 | .289 | 1.423| .808/ 2.506             |
| Gender                   | 1.190| .481 | 3.288*| 1.281/ 8.441           |
| (M = 0, F = 1)           |      |      |      |                         |
| Employment               | 2.315| .699 | 10.129**| 2.572/ 39.882         |
| (Y = 0, N = 1)           |      |      |      |                         |
| **Class 3**              |      |      |      |                         |
| Age                      | .041 | .021 | 1.042*| 1.000/ 1.086           |
| Education                | -.059| .291 | .942 | .533/ 1.666            |
| Gender                   | .221 | .487 | 1.248| .481/ 3.238            |
| (M = 0, F = 1)           |      |      |      |                         |
| Employment               | 2.122| .706 | 8.347**| 2.092/ 33.305         |
| (Y = 0, N = 1)           |      |      |      |                         |

*Note: B = Estimate, SE = Standard Error, OR = Odds Ratio, * = p < .05, ** p < .01, *** p < .001*
Table 5: Odds ratios, confidence intervals (95%) for health-related factors

| Reference Group: Class 1 | B   | SE  | OR   | 95% Confidence Interval | Lower | Upper |
|--------------------------|-----|-----|------|-------------------------|-------|-------|
| Class 2                  |     |     |      |                         |       |       |
| BMI (kg/m²)              | -.083 | .039 | .921 * | .853 - .994            |       |       |
| Handgrip (kg)            | .044  | .030 | 1.045 | .985 - 1.108           |       |       |
| PG-SGA                   | -.422 | .069 | .656 *** | .573 - .750        |       |       |
| Diagnosed within past 2yrs (N = 0, Y = 1) | -.914 | .575 | .401 | .130 - 1.238         |       |       |
| Receiving treatment      | -.428 | .586 | .652 | .207 - 2.055         |       |       |
| Class 3                  |     |     |      |                         |       |       |
| BMI (kg/m²)              | -.059 | .036 | .943 | .878 - 1.012         |       |       |
| Handgrip (kg)            | -.006 | .029 | .994 | .940 - 1.052         |       |       |
| PG-SGA                   | -.191 | .046 | .826 *** | .755 - .904     |       |       |
| Diagnosed within past 2yrs (N = 0, Y = 1) | -1.124 | .533 | .325 * | .114 - .923       |       |       |
| Receiving treatment      | -.237 | .538 | .789 | .275 - 2.265         |       |       |

*Note: B = Estimate, SE = Standard Error, OR = Odds Ratio, * = p < .05, ** p < .01, *** p < .001
Figures

Figure 1: Probability of clinical importance for each of the latent classes for the 14 domains of the EORTC QLQ-C30.

References

1. Peters E, Mendoza Schulz L, Reuss-Borst M. Quality of life after cancer-How the extent of impairment is influenced by patient characteristics. BMC Cancer. 2016;16(1):787-. doi:10.1186/s12885-016-2822-z.
2. Waldmann A, Pritzkeilt R, Raspe H, Katalinic A. The OVIS study: health related quality of life measured by the EORTC QLQ-C30 and -BR23 in German female patients with breast cancer from Schleswig-Holstein. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2007;16(5):767-76. doi:10.1007/s11136-006-9161-5.
3. Koch L, Jansen L, Herrmann A, Stegmaier C, Holleczek B, Singer S et al. Quality of life in long-term breast cancer survivors - a 10-year longitudinal population-based study. Acta oncologica (Stockholm, Sweden). 2013;52(6):1119-28. doi:10.3109/0284186x.2013.774461.
4. Tanaka K, Akichi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. Journal of pain and symptom management. 2002;23(5):417-23. doi:10.1016/s0885-3924(02)00376-7.
5. Deshields TL, Potter P, Olsen S, Liu J. The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year. Supportive Care in Cancer. 2014;22(4):1089-96. doi:10.1007/s00520-013-2049-3.
6. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. The oncologist. 2007;12 Suppl 1:4-10. doi:10.1634/theoncologist.12-S1-4.
7. Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001;19(14):3385-91. doi:10.1200/jco.2001.19.14.3385.
8. Borneman T, Piper BF, Koczywas M, Munever CM, Sun V, Uman GC et al. A qualitative analysis of cancer-related fatigue in ambulatory oncology. Clin J Oncol Nurs. 2012;16(1):E26-32. doi:10.1188/12.CJON.E26-e32.
9. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. The oncologist. 2000;5(5):353-60. doi:10.1634/theoncologist.5-5-353.
10. Coates A, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer. 1993;29a(12):1731-4. doi:10.1016/0959-8049(93)90115-v.
11. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(8):1355-63. doi:10.1200/jco.2007.13.3439.
12. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38(10):1351-7. doi:10.1016/s0959-8049(02)00098-9.
13. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in
international clinical trials in oncology. Journal of the National Cancer Institute. 1993;85(5):365-76. doi:10.1093/jnci/85.5.365.

14. Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Annals of Oncology. 2011;22(10):2179-90. doi:https://doi.org/10.1093/annonc/mdq721.

15. Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of Patient-Reported Outcomes in Routine Medical Care. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2018;38:122-34. doi:10.1200/edbk_200383.

16. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(4):714-24. doi:10.1200/jco.2004.06.078.

17. Wintner LM, Sztankay M, Aaronson N, Bottomley A, Giesinger JM, Groenvold M et al. The use of EORTC measures in daily clinical practice-A synopsis of a newly developed manual. Eur J Cancer. 2016;68:73-81. doi:10.1016/j.ejca.2016.08.024.

18. Klinkhammer-Schalke M, Koller M, Steinger B, Ehret C, Ernst B, Wyatt JC et al. Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer. British journal of cancer. 2012;106(5):826-38. doi:10.1038/bjc.2012.4.

19. Gulbrandsen N, Hjermstad MJ, Wisløff F. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. European journal of haematology. 2004;72(3):172-80. doi:10.1046/j.0902-4441.2003.00195.x.

20. Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F et al. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. Journal of Clinical Epidemiology. 2020;118:1-8. doi:https://doi.org/10.1016/j.jclinepi.2019.10.003.

21. Pt-Global. Patient Generated Subjective Global Assesment (PG-SGA). 2014. http://pt-global.org/?page_id=13. Accessed 05/08/2020.

22. Jager-Wittenaar H, Ottery FD. Assessing nutritional status in cancer: role of the Patient-Generated Subjective Global Assessment. Current opinion in clinical nutrition and metabolic care. 2017;20(5):322-9. doi:10.1097/mco.0000000000000389.

23. Field. A. Discovering Statistics Using SPSS. 3rd ed. London: Sage Publications Ltd.; 2009.

24. Kline P. The Handbook of Psychological Testing. New York: Taylor and Francis; 2000.

25. Tein JY, Coxe S, Cham H. Statistical Power to Detect the Correct Number of Classes in Latent Profile Analysis. Structural equation modeling : a multidisciplinary journal. 2013;20(4):640-57. doi:10.1080/10705511.2013.824781.

26. Wang J, & Wang, X.,. Structural equation modeling: Applications using Mplus. . Chichester, West Sussex: Wiley; 2012.

27. Muthén LK, & Muthén, B. O., . Mplus User’s Guide. Sixth Edition. Los Angeles, CA: Muthén & Muthén 2010.

28. Yuan K-H, Bentler PM. Three Likelihood-Based Methods For Mean and Covariance Structure Analysis With Nonnormal Missing Data. Sociological Methodology. 2000;30(1):165-200. doi:10.1111/0081-1750.00078.

29. Akaike H. Factor analysis and AIC. Psychometrika. 1987;52(3):317-32. doi:10.1007/BF02294359.

30. Schwarz G. Estimating the Dimension of a Model. The Annals of Statistics. 1978;6(2):461-4.

31. Sclove SL. Application of model-selection criteria to some problems in multivariate analysis. Psychometrika. 1987;52(3):333-43. doi:10.1007/BF02294360.

32. Lo Y, Mendell NR, Rubin DB. Testing the Number of Components in a Normal Mixture. Biometrika. 2001;88(3):767-78.
33. Nylund KL, Asparouhov T, Muthén BO. Deciding on the Number of Classes in Latent Class Analysis and Growth Mixture Modeling: A Monte Carlo Simulation Study. Structural Equation Modeling: A Multidisciplinary Journal. 2007;14(4):535-69. doi:10.1080/10705510701575396.

34. Storey DJ, Waters RA, Hibberd CJ, Rush RW, Cargill AT, Wall LR et al. Clinically relevant fatigue in cancer outpatients: the Edinburgh Cancer Centre symptom study. Ann Oncol. 2007;18(11):1861-9. doi:10.1093/annonc/mdm349.

35. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000;11(8):971-5. doi:10.1023/a:1008318932641.

36. Brown DJ, McMillan DC, Milroy R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer. 2005;103(2):377-82. doi:10.1002/cncr.20777.

37. Simmonds MJ. Physical function in patients with cancer: psychometric characteristics and clinical usefulness of a physical performance test battery. Journal of pain and symptom management. 2005;24(4):404-14. doi:10.1016/s0885-3924(02)00502-x.

38. Wen CP, Wai JPM, Tsai MK, Yang YC, Cheng TYD, Lee M-C et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. The Lancet. 2011;378(9798):1244-53. doi:10.1016/S0140-6736(11)60749-6.

39. Brown JC, Winters-Stone K, Lee A, Schmitz KH. Cancer, physical activity, and exercise. Comprehensive Physiology. 2012;2(4):2775-809. doi:10.1002/cphy.c120005.

40. Douglas E. Exercise in cancer patients. Physical Therapy Reviews. 2005;10(2):71-88. doi:10.1179/108331905X43490.

41. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. The Cochrane database of systematic reviews. 2012;2012(8):CD008465. doi:10.1002/14651858.CD008465.pub2.

42. Lis CG, Gupta D, Lammersfeld CA, Markman M, Vashi PG. Role of nutritional status in predicting quality of life outcomes in cancer—a systematic review of the epidemiological literature. Nutrition journal. 2012;11:27. doi:10.1186/1475-2891-11-27.

43. Marín Caro MM, Laviano A, Pichard C. Nutritional intervention and quality of life in adult oncology patients. Clinical Nutrition. 2007;26(3):289-301. doi:https://doi.org/10.1016/j.clnu.2007.01.005.

44. Bower JE. Behavioral symptoms in patients with breast cancer and survivors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(5):768-77. doi:10.1200/JCO.2007.14.3248.

45. Bubis LD, Davis L, Mahar A, Barbera L, Li Q, Moody L et al. Symptom Burden in the First Year After Cancer Diagnosis: An Analysis of Patient-Reported Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36(11):1103-11. doi:10.1200/jco.2017.76.0876.

46. Barbera L, Seow H, Howell D, Sutrakhar R, Earle C, Liu Y et al. Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer. 2010;116(24):5767-76. doi:10.1002/cncr.25681.

47. Frigozzin A, Uziely B, Musgrave CF. The relationship between symptom severity and symptom interference, education, age, marital status, and type of chemotherapy treatment in Israeli women with early-stage breast cancer. Oncol Nurs Forum. 2010;37(6):E411-8. doi:10.1188/10.Onf.E411-e418.

48. Yanick R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Jama. 2001;285(7):885-92. doi:10.1001/jama.285.7.885.

49. Hensel M, Egerer G, Schneeweiss A, Goldschmidt H, Ho AD. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol. 2002;13(2):209-17. doi:10.1093/annonc/mdf031.
50. Abdelsattar ZM, Wong SL, Regenbogen SE, Jomaa DM, Hardiman KM, Hendren S. Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening. Cancer. 2016;122(6):929-34. doi:10.1002/cncr.29716.

51. Cheung WY, Le LW, Gagliese L, Zimmermann C. Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2011;19(3):417-23. doi:10.1007/s00520-010-0865-2.

52. Cleeland CS, Zhao F, Chang VT, Sloan JA, O’Mara AM, Gilman PB et al. The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer. 2013;119(24):4333-40. doi:10.1002/cncr.28376.

53. Kenzik KM, Martin MY, Fouad MN, Pisu M. Health-related quality of life in lung cancer survivors: Latent class and latent transition analysis. Cancer. 2015;121(9):1520-8. doi:10.1002/cncr.29232.